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ABSTRACT
A detailed understanding of the interactions and the best dose-fractionation scheme of radiation to maximize
antitumor immunity have not been fully established. In this study, the effect on the host immune system of a single
dose of 20 Gy through intraoperative radiation therapy (IORT) on the surgical bed in low-risk breast cancer patients
undergoing conserving breast cancer has been assessed. Peripheral blood samples from 13 patients were collected
preoperatively and at 48 h and 3 and 10 weeks after the administration of radiation. We performed a flow cytometry
analysis for lymphocyte subpopulations, natural killer cells (NK), regulatory T cells (Treg) and myeloid-derived
suppressor cells (MDSCs). We observed that the subpopulation of NK CD56+high CD16+ increased significantly
at 3 weeks after IORT (0.30–0.42%, P < 0.001), while no changes were found in immunosuppressive profile,
CD4+CD25+Foxp3+Helios+ Treg cells, granulocytic MDSCs (G-MDSCs) and monocytic MDSCs (Mo-MDSCs).
A single dose of IORT may be an effective approach to improve antitumor immunity based on the increase in NK
cells and the non-stimulation of immunosuppressive cells involved in immune escape. These findings support future
combinations of IORT with immunotherapy, if they are confirmed in a large cohort of breast cancer patients.
Keywords: immune system; immunomodulation; flow cytometry; immunophenotyping; breast cancer;
intraoperative radiation therapy
INTRODUCTION
Breast cancer is the most common malignancy and the second high-
est cause of death in women worldwide [1]. The molecular mecha-
nisms of breast cancer, particularly tumor cell immune evasion from
the host immune response, have been the focus of intense research.
The immune system appears to play an essential role in the initiation
of breast cancer, progression and response to treatment, given that
immune activation is associated with a higher pathological response
[2]. The current treatment for early-stage breast cancer is breast con-







/jrr/article/62/1/110/5912577 by guest on 01 M
arch 2021
Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer • 111
preferential site of relapse. Increased local control is associated with
improved overall survival, so events close to the tumor bed are crucial
for the final prognosis [3]. Several trials have evaluated various tech-
niques of accelerated partial breast irradiation (APBI) of the lumpec-
tomy bed vs conventional whole-breast irradiation in terms of efficacy
and other outcomes [4, 5]. The results indicate that treatment with
intraoperative radiation therapy (IORT) yields similar results in terms
of survival and toxicity as whole-breast radiation therapy, with the
benefit of reduced treatment time. In this context, IORT has been
established as a good option for patients’ treatment in early-stage breast
cancer undergoing conserving surgery, or in combination with external
beam radiation therapy (EBRT) in patients with risk factors [4, 6].
Research on the interactions between radiation therapy and the
immune system has shown new mechanisms that can be exploited to
improve the efficacy of radiotherapy [7, 8]. Radiobiology has focused
on normo-fractionated schemes, but little is known about the biolog-
ical effects of high doses per fraction. Radiotherapy can induce the
release of antigens during the death of cancer cells that, in associa-
tion with proinflammatory signals, activate the innate immune sys-
tem by inducing the activation of specific T cells against the tumor.
Radiotherapy also has effects on the tumor microenvironment, favor-
ing the infiltration of activated T lymphocytes and overcoming some
of the barriers of antitumor rejection [9, 10]. However, radiother-
apy exerts immune inhibitory effects too. The limited availability of
intratumoral dendritic cells to present radiation-released antigens and
the increase in the irradiated tumor microenvironment of differents
factors, including, e.g. transforming growth factor (TGF) β and imm-
nusopressive cells, such as myeloid-derived suppressor cells (MDSC)
and regulatory T (Treg) cells, are part of theses immune inhibitory
effects [11]. Studies have shown that conventional fractional EBRT
produces an increase in both the levels of MDSCs and Treg cells
characterized by systematically expanding and promoting T cell dys-
function [12]. However, it has been reported that the highest single
doses applied in hypo-fractionated schemes are more advantageous for
stimulating the immune system [7, 9]. Hypo-fractionated radiotherapy
inhibits hypoxia and reduces the recruitment of immunosuppressive
cells into primary tumors, generating a microenvironment with lower
Programmed Death-Ligand (PD-L1), releasing the inhibition on cyto-
toxic CD8+ and boosting not only the local but also systemic anti-
cancer immunity [13]. This approach has been explored in radiother-
apy techniques using high-dose fractionations such as stereotactic body
radiotherapy (SBRT) [14].
IORT involves precise delivery of a large dose of ionizing radi-
ation to the tumor bed, which is the area of higher risk of relapse.
Although conclusive data on immune reactions and IORT are not
available, it is likely that the single high doses administered during
IORT cause immunogenic cell death of cancer cells remaining in situ
after surgery by activation of the immune system [15]. There are some
published investigations on the effect of IORT on tumor cells as well as
wound fluid [16–18]. The results suggest that higher radiation doses
result in increased tumor cell necrosis and antigen presentation, and
recruitment of T-cells to irradiated and possibly distant unirradiated
tumors, providing an additional reason to investigate IORT anew, per-
haps in combination with immune checkpoint blockade treatments
[19, 20]. Therefore, systemic functional changes in response to high
doses of radiotherapy delivered in the tumor bed by IORT as a single
treatment modality were investigated in this preliminary study. We
assessed changes in peripheral blood immune cell composition after
IORT on the surgical bed in patients with low-risk breast cancer. The
information provided by this study could be useful to suggest new com-
binations and timings of IORT and immunotherapy in breast cancer
patients.
MATERIALS AND METHODS
The pilot study protocol was approved by the Clinical Research Eth-
ical Committee of the hospital (protocol code IORT-01, reference
PR009/16), and written informed consent was obtained from all par-
ticipants. From October 2016 to September 2018, a total of 13 patients
diagnosed with low-risk breast cancer (T1N0M0 and T2N0M0) who
were candidates for breast-conserving surgery and IORT were eligi-
ble to participate in the study. Inclusion criteria were as follows: age
>50 years, histologically proven invasive ductal carcinoma <3.5 cm,
low-risk luminal A subtype (estrogen-receptor and/or progesterone-
receptor positive), HER2 negative, and protein Ki-67 <20%, without
lymph node involvement (N0) adequate for breast-conserving surgery
and IORT (lesion distance to skin or breast wall ≥0.7 cm), as well
as capacity to understand the characteristics of the study and to give
informed consent. Exclusion criteria were the presence of bilateral
breast cancer at the time of diagnosis, a previous history of malig-
nant disease except for non-melanoma skin cancer, need for treatment
with chemotherapy, and state of immunosuppression, both current and
developed during follow-up, caused by immunosuppressant medica-
tions or systemic disorders. For each patient, the postoperative patho-
logical report was reviewed, and when high-risk factors were found,
such as grade 3 tumor differentiation, lymphovascular invasion, triple-
negative breast cancer subtype, positive nodes and affected margins or
close margins <5 mm without re-excision, these cases were excluded
from the analysis. Patients with these characteristics underwent EBRT
with or without prior chemotherapy.
Intraoperative radiotherapy was administered using the INTRA-
BEAM system (Carl Zeiss Surgical, Oberkochen, Germany) emitting
low-energy (50 kV) photons at a high dose-rate to the target tumor
bed volume, with rapid dose fall-off and hence limited exposure to
adjacent non-tumor tissues [21]. Spherical applicators were used to
deliver a uniform dose at the inner-surface of the breast lumpectomy
cavity. The size of the applicator used in each case was based on the
largest one that fits comfortably to the tumor bed so that the skin and
subcutaneous tissue can be fixed with a suture on the bag over the
sphere. The applicator was kept at least 0.7 cm from the skin. The
dose rate varied according to the diameter of the applicator and the
energy of the beam. A single dose of 20 Gy (in water) was prescribed
and delivered in a period of 15–35 min, depending on the size of the
applicator. IORT was administered immediately after removal of tumor
volume when R0 resection was obtained.
Flow cytometry
Peripheral blood samples (9 mL) drawn in ethylenediaminetetraacetic
acid (EDTA) were obtained preoperatively before surgery and IORT,
and at 48 h and 3 and 10 weeks after IORT. Fresh blood was used, and
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Blood (50–100 μL) of blood was added to the appropriate tubs, and
cells were processed according to the manufacturer’s instructions. The
antibody panels used were the following: lymphocyte phenotyping
panel (DuraCloneTM, Beckman Coulter Life Sciences, Indianapolis,
IN, USA): CD16, CD56, CD19, CD14, CD4, CD8, CD3 and CD45
antibodies; regulatory T cells panel (DuraCloneTM, Beckman Coulter
Life Sciences): CD45RA, CD25, CD39, CD3, CD45, CD4, Helios and
intracellular Foxp3 antibodies; and myeloid-derived suppressor cells
panel (DuraCloneTM, Beckman Coulter Life Sciences): CD45, HLA-
DR, CD14, CD33 and CD11b antibodies.
All flow cytometry data were acquired on a 10-color/3-laser Gallios
flow cytometer (Beckman Coulter). The instrument has not been
altered. The stability of the flow cytometer was assured through a qual-
ity control procedure using Flow-Check Pro Fluorospheres (Beckman
Coulter). A compensation matrix for each panel was created using the
compensation tubes supplied with each panel, according to manufac-
turer’s instructions. A minimum number of 100 000 leucocytes for
lymphocyte phenotyping, 100 000 leucocytes for MDSC analyses and
40 000 leucocytes for regulatory T cell analysis was established [22,
23]. Data were manually analyzed using FlowJo software v. 10.5 (Tree
Star Inc., Ashland, OR, USA).
Statistical analysis
Categorical data are expressed as frequencies and percentages, and
continuous data as median and range. Friedman one-way Analysis of
Variance (ANOVA) was used to compare changes of cell populations
at different time periods and the Wilcoxon signed-rank test to assess
differences in the cell populations at different time periods as compared
to each baseline. Statistical significance has been confirmed by Conover
post hoc test.
Statistical significance was set at P < 0.05. Data were analyzed using
the R statistical program (version 3.5.0).
RESULTS
A total of 13 women diagnosed with early-stage breast cancer were
included in the study. The salient characteristics of these patients are
shown in Table 1. The median age was 66 years (range 61–85 years).
Most lesions were located in the upper outer quadrant (69.2%) of
the left breast (84.6%). The most common form was the T1 stage
(92.3%). In all patients, the histological diagnosis was infiltrating ductal
carcinoma, luminal subtype. All patients received hormonal therapy.
The most common size of the applicator was 3.5 cm (61.5% of the
cases), with a mean treatment time of 19 min. No relapse was observed,
and after a median follow-up time of 14 months, 100% of patients
remained alive without disease.
Immunophenotyping panel
Of the 52 samples obtained at different time intervals in the course
of IORT, 44 were analyzed. The flow cytometry gating strategy used
for the analysis of all cell types is shown in Fig. 1. Lymphocytes were
identified from CD45. T lymphocytes were distinguished from total
lymphocytes using the characteristic CD3 marker. From these, CD4+
helper lymphocytes were separated from CD8+ cytotoxic. B lympho-
cytes were identified by characterization CD3− CD19+. To select the
Table 1. Characteristics of 13 patients with low-risk breast
cancer; data are presented as frequencies with percentages in
parenthesis unless otherwise stated
n (%)









Estrogen receptor positive 13 (100)
Progesterone receptor positive 10 (76.9)
Progesterone receptor negative 3 (23.1)









Treatment time, min, median
(range)
19 (18–28)
Hormone therapy 13 (100)
Tamoxifen 8 (61.5)
Letrozole 5 (38.5)
NK cells, a negative selection of the CD3− CD19 −CD20− markers
was made; subsequently through the combination of CD56 and CD16,
subpopulations of NK cells were obtained.
Changes of total lymphocytes (CD45+) along the study period
after the administration of IORT were not statistically significant
(Friedman one-way ANOVA, P = 0.356). Also, differences in the
paired comparisons (different time points vs baseline) were not
statistically significant (Wilcoxon signed-rank test, P = 0.5, 0.95, 0.81
at 48 h, 3 and 10 weeks, respectively) (Fig. 2A). When the different
lymphocyte cell subpopulations were assessed, a progressive decrease
in CD19+ B cells was observed from 48 h after IORT, reaching
minimal values at 10 weeks (Friedman one-way ANOVA, P = 0.007).
Although no statistically significant differences were found when the
percentage of B cells in the baseline (7.38%) was compared with that
found 10 weeks after IORT (5.91%), a trend towards significance
was found (Wilcoxon signed-rank test, P = 0.062) (Fig. 2B). The
subpopulation of T helper cells CD3+ CD4+ did not reveal any
significant statistical differences among the different comparisons
performed, although a slight decrease after IORT as compared to
baseline (34.20%), reaching minimal values 10 weeks after irradiation
(30.60%), was observed (Fig. 2C). By contrast, changes in CD3+
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Fig. 1. Immunophenotyping panel for the detection of different populations and subpopulations of lymphocytes and NK cells.
period, with the highest values at 10 weeks as compared with baseline
(67.10 vs 60.20%), but these differences did not reach statistical
significance either when the changes of cell populations at different
time periods or when the different time periods were compared with
the baseline (Fig. 2D). The CD4+/CD8+ ratio showed an increase
in cytotoxic lymphocytes from 0.56 to 0.45% at 10 weeks, but this
change was not statistically significant (Wilcoxon signed-rank test,
P = 0.58) (Fig. 2E).
In the subpopulation of NK cells defined as CD56dim CD16+,
there was a decrease from baseline to 48 h, but the difference was not
significant. Differences between 3 and 10 weeks were not significant,
although we observed a slight increase when compared with the
baseline (Fig. 2F). In the population of NK cells with activated
phenotype defined as CD56+high CD16+, differences along the study
period after the administration of IORT were significant (Friedman
one-way ANOVA, P = 0.007). When the different time periods were
compared with the baseline there was a significant increase at 3 weeks
compared with the baseline (0.30–0.42%, Wilcoxon signed-rank test,
P = 0.001) (Fig. 2H). On the other hand, in the subpopulations
of CD56dim CD16− and CD56+high CD16−, changes were not
statistically significant in either of the comparisons by Friedman’s test
or the Wilcoxon’s test for paired comparisons at different time points
vs baseline (Fig. 2G and I). In the subpopulation of CD56−CD16+,
there was an increase from 13.20% at baseline to 15.80% at 10 weeks,
but these differences were not statistically significant using Wilcoxon’s
test (P = 0.3125) nor for the comparisons at 48 h and 3 weeks. Also,
differences were not significant when changes of cell populations at
different time periods were compared (Friedman’s test, P = 0.05)
(Fig. 2J).
Treg cells
The strategy used for the analysis of different phenotypic and
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Fig. 2. Median values of CD45+ cell population (A), CD19+ (B), helper T cells CD3+ and CD4+ (C), cytotoxic T cells CD3+
CD8+ (D), lymphocytes T cells ratio (CD4+/CD8+) (E), NK cells (CD56dim CD16+) (F), NK cells (CD56dim CD16−) (G),
NK cells (CD56high CD16+) (H), NK cells (CD56high CD16−) (I) and NK cells (CD56−CD16+) (J). ∗P < 0.05 when
Wilcoxon’s signed-rank test was applied.
Fig. 3. Immunophenotyping panel for regulatory T cells.
scattering and forward scattering characteristics, which were addition-
ally blocked for CD4+ T cells. Then, CD4+ T cells were examined
for CD4+ CD25+ Foxp3+ Helios+ cell populations. Treg cells were
also divided into functional subsets based on CD45RA and Foxp3
expression. The representative diagrams of flow cytometry for the
analysis of all cell types are shown in Fig. 3.
When changes in the cell populations at different timepoints were
compared with the baselines, a slightly decreased CD3+ CD4+ CD25+
Foxp3+ Helios+ cell population was observed at 48 h after the admin-
istration of IORT, with the lowest values at 3 weeks (27 vs 38.50%
at baseline), although no significant differences were observed in any
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Fig. 4. Median values of the CD4+ CD25+ Foxp3+ Helios+ cell population (A) and CD4+ CD25+ Foxp3+ CD45RA− (B) during
the study period at different time points.
Foxp3+ subset at different timepoints were not observed (Friedman’s
test, P = 0.277) (Fig. 4A and B).
MDSCs
Representative diagrams of flow cytometry for the analysis of all cell
types are shown in Fig. 5. MDSCs were defined as CD45 + CD33 + CD
-11b + cells. Then, MDSC cells were also divided into subsets based on
CD14 and HLA-DR expression.
Statistically significant changes in the overall MDSC population
were not observed (Fig. 6A). For granulocytic MDSCs (G-MDSC)
characterized as CD33+ CD11b+ CD14− and monocytic MDSCs
(Mo-MDSC) characterized as CD33+ CD11b+ CD14+ HLADR−/low,
statistically significant differences were not found. Both in the G-
MDSC and Mo-MDSC subsets, median percentages at different time
points as compared with baseline were not statistically significant.
Similar results were obtained when changes along the study period
after the administration of IORT were assessed with Friedman’s test
(G-MDSC, P = 0.471; Mo-MDSC, P = 0.782) (Fig. 6B and C).
DISCUSSION
Results presented in this study indicate that treatment with IORT in
low-risk breast cancer patients undergoing conserving breast surgery
can affect the balance of immune cells in the peripheral blood. Dur-
ing the study period, we noted that radiation therapy increased the
presence of peripheral NK cells while no changes were detected in the
immunosuppressive profile, characterized by Treg cells and MDSCs.
Radiation therapy can cause apoptosis of T cells and lymphopenia
[24]. In the present study, statistically significant differences in the
total number of peripheral blood lymphocytes were not found, but
the population of B lymphocytes experienced a decrease after IORT,
reaching its lowest values at 10 weeks. For the different subpopulations
of T lymphocytes, a progressive increase in cytotoxic T lymphocytes
throughout the study period was observed. The CD4+/CD8+ ratio
showed an increase of cytotoxic lymphocytes at 10 weeks as compared
to baseline values. Differences, however, did not reach statistical signif-
icance probably due to the limited number of patients included in the
study. Recent evidence suggests that T cells have an important function
in regulating cancer growth. Several T cells play a critical role in the
balance of anti- and pro-tumor immune responses within the tumor
microenvironment as well as in the systemic circulation [25, 26]. In
fact, cytotoxic T cells are the main final effectors of tumor cell death.
However, Treg cells generally suppress or downregulate the induction
and proliferation of cytotoxic cells. Therefore, the dominance of cyto-
toxic T lymphocytes is a favorable prognostic factor in cancer [27, 28].
We found significant changes in the subpopulation of NK cells
in breast cancer patients treated with IORT. There is evidence
that irradiation-induced tissue injury increases the expression of
NK-activating ligands (e.g. NKG2D ligands) on malignant cells,
thereby rendering tumors more susceptible to NK cell cytotoxic
activity, modulating the immune response by increasing antigenicity
and upregulating the expression of proinflammatory cytokines and
chemokines [28, 29]. CD56dim NK cells have a high cytotoxic activity
and express high levels of perforin; in addition, the high expression
CD16 makes them efficient mediators of antibody-dependent cellular
cytotoxicity. CD56+ CD16− NK cells have a lower cytotoxic capacity
but are the most efficient cytokine producers, including interferon-γ
(IFN-γ ), tumor necrosis factor-α (TNF-α), Interleukin-12 (IL-12),
IL-15 and granulocyte and monocyte colony-stimulating factor [30].
In the present study, the subset CD56dim CD16+ NK cells showed
an increase after 3 weeks of IORT and continued to increase until
the end of the follow-up period (46.20–55.80%). The CD56− subset
expressing CD16 at high density, but showing functional alterations
due to its low cytotoxic activity and cytokine production [28],
presented variations during the study period. Although there was a
decrease at 48 h, the percentage of cells increased at 3 and 10 weeks. We
observed that the only significant increase was in the subset CD56high
CD16+ NK cells, especially at 3 weeks (0.30–0.42%). CD56highCD16+
NK cells are characterized by NKG2A and low levels of perforin, and
are primarily specialized for cytokine production. In peripheral blood
these NK cells express CD62L, CCR7, CXCR4 and CXCR3 that
allows their preferential recruitment to secondary lymphoid organs,
tumors and inflamed tissues [31]. One of the factors responsible for
the variations in the percentage of these cells during our study period
could be the presence of cytokine release, especially the overexpressed
TGF-β molecule after irradiation. In vivo studies in breast cancer
patients have shown a positive correlation of TGF- β1 with NKG2A
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Fig. 5. Immunophenotyping panel for MDSCs.
Fig. 6. Median values of MDSCs (A), G-MDSCs (B), and Mo-MDSCs (C) during the study period at different time points.
in these regulatory mechanisms [32]. These findings indicate that a
single radiation dose might increase the number of these cells that have
antitumor capacity. The identification of NK cell subsets endowed
with particular functional capabilities might help monitor residual
antitumor NK cell-mediated responses in breast cancer patients.
Treg cells can promote tumor progression by inhibiting effective
antitumor immunity. These cells are more resistant to ionizing radi-
ation than conventional CD4+ T cells and show a relative increase
after radiotherapy [33–35]. In our study, the percentage of peripheral
blood CD4+ CD25+ Foxp3+ Helios+ Treg cells did not experience
significant change during the study period. This relevant finding indi-
cates that the use of this single high-dose approach may be essential
to neutralize these immunosuppressive cells, which are one of the
main components of immune escape. In recent years, there has been
great interest in promoting the production of more efficient Treg cells
enhancing antitumor activity [36]. In this respect, assessment of Treg
cell levels and related cytokines in the peripheral blood may be impor-
tant to guide individualized treatments in breast cancer.
It has been shown that the prevalence of MDSCs with immuno-
suppressive activities is an important mechanism of tumor escape.
In mouse models, accumulated evidence has demonstrated the
importance of MDSCs in the development and progression of breast
cancer [37]. Gonda et al. [38] examined MDSC levels in 155 patients
with breast cancer. MDSCs in circulating peripheral blood increased
in patients with breast cancer compared to healthy volunteers. Also,
the levels of MDSCs in preoperative patients and in patients with
recurrent breast cancer were significantly higher compared with
postoperative patients, patients with recurrent breast cancer who
received chemotherapy and healthy volunteers. Studies have shown
that RT, especially conventional fractional RT, produces an increase
in the levels of MDSCs characterized by being more resistant to
radiation [9, 39]. However, in our study, changes in the overall MDSCs
population as well as in G-MDSC and Mo-MDSC subpopulations
were not observed. This finding is in line with the results previously
published by our group in patients with lung cancer. We also observed
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stereotactic body radiotherapy (SBRT), did not produce an increase
in the percentage of MDSCs when analyzed in peripheral blood.
Indeed a significant decrease in the percentage of granulocytes was
observed 6 months after the administration of radiation. These results
may show the possible benefit of the application of this type of
scheme, which seems to be more effective in controlling cells related to
immunosuppression [40].
In this respect, studies have been developed to test if hypofraction-
ated dose schedules may be more effective than conventional fraction-
ated radiotherapy. In an experimental study of mice bearing murine
melanoma treated with up to 15 Gy radiation given in various-size
fractions, Schaue et al. [41] found that fractionated treatment with
medium-size radiation doses of 7.5 Gy/fraction gave the best tumor
control and tumor immunity while maintaining low Treg cells num-
ber. In a preclinical study, Lee et al. [42] compared a single 20 Gy
dose with 5Gy x 4 over 2 weeks. Ablative 20 Gy radiation dramat-
ically increased T-cell priming in draining lymphoid tissues, leading
to reduction/eradication of the primary tumor or distant metastasis
in a CD8+ T cell-dependent fashion, whereas fractionated radiation
therapy showed a lower inhibition of tumor growth. However, the best
dose-fractionation regimen to maximize antitumor immunity remains
to be established.
In this preliminary study, we show that the administration of a
single dose of IORT altered the balance of peripheral immune cells
by increasing NK cells but did not produce changes in Treg cells or
MDSCs. No previous studies have evaluated the effect of IORT on
peripheral immune cells in breast cancer patients. We therefore con-
sider that these results help to clarify the interactions of IORT with the
host immune system and add evidence to suggest IORT utilization as
an attractive alternative to whole-breast irradiation in selected patients
with early-stage breast cancer. However, given the exploratory nature of
our study, more studies are needed, with a greater number of patients
and a control group of patients receiving hypofractionated whole-
breast irradiation, to support the use of the combination of IORT with
immunotherapy as a new therapeutic option in breast cancer patients.
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